DBpedia – Linked Data Fragments

Matches in DBpedia 2015-10 for { ?s ?p "Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously. Catabasis uses a proprietary linker technology to conjugate two drugs that act on different nodes of a disease pathway, with the intent of improving safety and efficacy of the two components. The conjugate is designed to keep the linked components inactive in plasma until they are cleaved by a specific class of intracellular enzymes, releasing both bioactives within the cells of target tissues.Catabasis has two programs in clinical development. CAT-2003, a conjugate of the B vitamin niacin and the omega-3 fatty acid eicosapentaenoic acid (EPA), is designed to treat severe hypertriglyceridemia and other lipid disorders and is currently in clinical testing. CAT-1004, a conjugate of the omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate, has completed Phase 1 testing; the drug is being developed for the treatment of inflammatory diseases such as inflammatory bowel disease and Duchenne muscular dystrophy. In the Phase 1 study, results showed that CAT-1004 was safe and well tolerated,and that the linker technology allowed the active components to inhibit the NF-kB pathway synergistically;, this pathway plays an important role in inflammation."@en }

• Catabasis_Pharmaceuticals abstract "Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously. Catabasis uses a proprietary linker technology to conjugate two drugs that act on different nodes of a disease pathway, with the intent of improving safety and efficacy of the two components. The conjugate is designed to keep the linked components inactive in plasma until they are cleaved by a specific class of intracellular enzymes, releasing both bioactives within the cells of target tissues.Catabasis has two programs in clinical development. CAT-2003, a conjugate of the B vitamin niacin and the omega-3 fatty acid eicosapentaenoic acid (EPA), is designed to treat severe hypertriglyceridemia and other lipid disorders and is currently in clinical testing. CAT-1004, a conjugate of the omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate, has completed Phase 1 testing; the drug is being developed for the treatment of inflammatory diseases such as inflammatory bowel disease and Duchenne muscular dystrophy. In the Phase 1 study, results showed that CAT-1004 was safe and well tolerated,and that the linker technology allowed the active components to inhibit the NF-kB pathway synergistically;, this pathway plays an important role in inflammation.".